<DOC>
	<DOCNO>NCT00053768</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug give drug different way may kill cancer cell . Radiation therapy use high-energy x-rays damage cancer cell . It yet know combination chemotherapy regimen follow radiation therapy effective treat aggressive non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two combination chemotherapy regimens follow radiation therapy compare well work treat patient aggressive non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Radiation Therapy Treating Patients With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy standard-dose v high-dose cyclophosphamide , doxorubicin , vincristine , etoposide , prednisone follow radiotherapy , term time treatment failure , patient aggressive non-Hodgkin 's lymphoma . - Compare acute long-term toxic effect regimens patient . - Compare complete response rate , survival tumor control , disease-free survival patient treat regimen . - Analyze time relapse radiotherapy patient . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord LDH level ( great upper limit normal [ ULN ] v great ULN ) , initial bulky disease ( yes v ) , stage ( I II v II IV ) , ECOG performance status ( 0 1 v 2 3 ) , participate center . Patients randomize 1 2 treatment arm follow : - Arm I ( Standard dose ) : Patients receive cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 ; etoposide IV day 1-3 ; oral prednisone day 1-5 ( CHOEP ) standard dos . - Arm II ( Escalated dose ) : Patients receive high-dose CHOEP arm I . Patients also receive filgrastim ( G-CSF ) subcutaneously day 6-12 . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion CHOEP chemotherapy , patient initial bulky disease extranodal involvement undergo radiotherapy 5 day week 4 week . Patients undergo radiotherapy follow 2 month radiotherapy . All patient ( include undergo radiotherapy ) follow every 3 month 2 year every 6 month 3 year . PROJECTED ACCRUAL : A total 552 patient accrue study within 4.75 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma Previously untreated disease Favorable prognosis International Prognostic Index score 01 No 25 % marrow involvement PATIENT CHARACTERISTICS : Age 18 60 Performance status ECOG 03 OR Karnofsky 40100 % Life expectancy Not specify Hematopoietic Platelet count least 100,000/mm^3 WBC least 2,500/mm^3 Hepatic No active hepatitis infection Renal Not specify Other HIV negative Not pregnant nursing No relevant accompany disease No concurrent malignancy No contraindication study medication No prior noncompliance patient PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify Other No concurrent participation another treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>